Kathleen P. Bloch - 13 Dec 2023 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: Chief Financial Officer
Issuer ticker: CTSO
Reported as of: 13 Dec 2023
Net transaction value: +$50,000
SEC form: 4
Accepted by SEC: 15 Dec 2023, 16:32:14 UTC
Prior SEC filing: 20 Sep 2023
Next SEC filing: 02 Apr 2024
Source filing: View source filing
Reporting owner signature: /s/ Kathleen P. Bloch

Key filing fact

Kathleen P. Bloch filed Form 4 for Cytosorbents Corp (CTSO) on 15 Dec 2023.

Key facts

This page summarizes Kathleen P. Bloch's Form 4 filing for Cytosorbents Corp (CTSO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Dec 2023, 16:32.

Change

Previous filing in this sequence was filed on 20 Sep 2023.
Current net transaction value: +$50,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Purchase

Transaction value: $50,000
Shares: +37,594
Change %: +8.7%
Price: $1.33
Shares after: 467,941
Date: 13 Dec 2023
Ownership: Direct
Footnotes: F1, F2, F3, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTSO transaction Derivative

Common Stock Warrant (Right to Buy)

Purchase

Transaction value
Shares: +13,157
Change %
Price
Shares after: 13,157
Date: 13 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,157
Exercise price: $2.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant

Footnote F2

Includes: (i) the following restricted stock units ("RSUs") (which vest as to 10,000 RSUs on the first anniversary of the date of grant, and 10,000 RSUs on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 20,000 RSUs granted on September 18, 2023;

Footnote F3

(continued from footnote 2) (ii) the following RSUs that will be settled into Common Stock upon a "Change In Control" of the Company, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;

Footnote F4

(continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date), and will be settled into Common Stock upon vesting: 18,500 RSUs granted on August 10, 2022; and

Footnote F5

(continued from footnote 4) (iv) 247,941 shares of Common Stock owned by the reporting person.